priors.science/reviews/heart-failure-management

Heart Failure Management

The current evidence on 21 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

21claims tracked
301primary papers reviewed
17 Aug 2026latest evidence review
Weeklyre-scored against new papers
9 Established · 8 Likely · 2 Uncertain · 2 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Sacubitril/valsartan does not reduce mortality in heart failure with preserved ejection fractionHFPEFEstablished90%10
SGLT2 inhibitors reduce mortality in heart failure with reduced ejection fractionPharmEstablished90%12
Beta-blockers reduce mortality in heart failure with reduced ejection fractionPharmEstablished90%16
SGLT2 inhibitors reduce heart failure hospitalisation in heart failure with preserved ejection fractionHFPEFEstablished88%12
Angiotensin receptor-neprilysin inhibitor reduces mortality versus ACE inhibitor or angiotensin receptor blocker in heart failure with reduced ejection fractionPharmEstablished87%10
Left ventricular assist device destination therapy improves survival in end-stage heart failureLvadEstablished86%20
Vericiguat reduces events in worsening heart failure with reduced ejection fractionNovelEstablished86%14
Vericiguat neutral for primary endpoint in stable heart failure with reduced ejection fractionNovelEstablished86%25
Mineralocorticoid receptor antagonist reduces mortality in heart failure with reduced ejection fractionPharmEstablished86%11
Finerenone reduces heart failure events in heart failure with mildly reduced or preserved ejection fractionHFPEFEarly evidenceLikely84%22
HeartMate 3 superior to axial-flow left ventricular assist devicesLvadLikely84%15
Acetazolamide improves decongestion in acute decompensated heart failureAdhfLikely83%12
Cardiac resynchronisation therapy reduces mortality in heart failure with reduced ejection fraction and left bundle branch blockCRTLong-standingLikely82%25
SGLT2 inhibitors improve outcomes in acute decompensated heart failureAdhfLikely77%11
Intravenous iron does not reduce all-cause mortality in heart failureIronLikely74%12
Primary prevention implantable cardioverter-defibrillator reduces sudden cardiac deathIcdLikely73%13
Intravenous iron reduces heart failure hospitalisationIronLikely70%9
Left bundle branch pacing achieves superior resynchronisation versus conventional biventricular cardiac resynchronisation therapyCRTUncertain58%25
Quadruple therapy superior to three-drug regimensPharmUncertain56%15
Cardiac resynchronisation therapy with defibrillator and with pacemaker have similar all-cause mortalityCRTLong-standingDoubtful40%19
Implantable cardioverter-defibrillator reduces all-cause mortality in the contemporary eraIcdDoubtful38%12
Track Heart Failure Management.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Early evidenceMost of this evidence is from the last two years.
Long-standingMost of this evidence is older than the rest of this field.